Q1 FY27 results analysis · August 14, 2026

Natco Pharma Ltd (NATCOPHARM) Q1 FY27 Results Analysis: Normalized PAT Surges 34%, Base Business Grows 18%

−57.0%PAT year on year, Rs. 206.50 Cr
Cofacto ResearchPublished August 14, 20262 min readNeutral read
Quick summary

Natco Pharma Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 735.20 Cr (-44.70% YoY) and PAT growth of -57.00% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 14, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 735.20 Cr (-44.70% YoY)
PAT (Q1)Rs. 206.50 Cr (-57.00% YoY)
EBITDA margin30.93% (-1457 bps YoY)
EPS (Q1)Rs. 11.53 (-57.00% YoY)
Market capRs. 16,166.97 Cr
CMPRs. 903.15

Quarter Snapshot

Revenue fell 44.7% YoY as expected from Revlimid exclusivity loss, but base business grew 17.7% YoY (above guided 10-15%) and normalized PAT improved 34.1% QoQ. Associate profit from Adcock Ingram provided a new earnings driver, and the EBITDA margin rebounded sequentially to 30.9%. The company's FY27 guidance remains on track, though the standalone entity is under pressure.

Key Investment Insights

Key Positives

  • Non-international business (API, Domestic Formulations, Crop Health Sciences) grew 17.7% YoY, exceeding the 10-15% guided range.
  • Normalized PAT improved 34.1% QoQ to Rs.206.5 Cr when adjusting for the one-time Q4 deferred tax credit.
  • EBITDA margin improved sequentially from 25.1% to 30.9%, demonstrating operating leverage.
  • Associate profit from Adcock Ingram contributed Rs.84.3 Cr, diversifying earnings away from the Revlimid dependency.
  • Interim dividend of Rs.1.50 per share declared.

Risk Factors

  • Revenue declined 44.7% YoY due to the expected loss of Revlimid exclusivity, highlighting the revenue cliff.
  • PAT to owners fell 57% YoY to Rs.206.5 Cr.
  • Finance costs surged 306% YoY to Rs.13.0 Cr due to debt taken on for the Adcock Ingram acquisition.
  • Standalone PAT declined 83.9% YoY to Rs.74.6 Cr, showing the parent entity's reliance on subsidiary contributions.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.